Image Analysis Group and Picture Health Announce Strategic Partnership

Olga Kubassova

Partnership marks a significant step forward in the application of AI and imaging analytics to improve patient outcomes and advance the future of healthcare.

Cleveland, OH and London, UK – May 30, 2025 – Image Analysis Group (IAG), a globally recognized imaging clinical research organization (iCRO) known for its deep medical expertise and cutting edge AI-powered trial solutions, and Picture Health, a leader in AI imaging biomarkers to accelerate oncology clinical development, today announced a strategic partnership to enhance the development and adoption of advanced imaging technologies in clinical research trials.

“Partnering with Picture Health aligns perfectly with our mission to harness the power of AI and imaging for precision clinical trials,” said Dr. Olga Kubassova, President and CEO of IAG. “By integrating our industry-leading platform DYNAMIKA™ with Picture Health’s impactful imaging biomarkers, we can deliver deeper insights and accelerate the development of life-changing oncology therapies.”

Impact

  • Together, the companies will provide life science organizations and healthcare providers with enhanced tools for early response detection, smarter patient stratification, and the prediction of oncology treatment outcomes.
  • Seamless data management & hot transfers: IAG will enable robust collection of imaging data for further analysis by Picture Health.
  • Actionable insights & analytics: Partner will enable bio-pharma clients to leverage AI and advanced imaging to improve early drug efficacy assessments in clinical trials. Enable more efficient handling and analysis of large-scale imaging data across multi-center studies.
  • AI in Oncology Trials: This collaboration will combine IAG’s international expertise in planning, executing, and managing clinical trials that rely on traditional and AI-driven endpoints and its proprietary cloud-based platform, DYNAMIKA with Picture Health’s multimodal AI biomarkers that integrate advanced radiomics and pathomics to extract biologically interpretable, predictive insights from standard-of-care imaging using its Px™ Platform.
  • Efficacy Evidence beyong RECIST: Support effective deployment of predictive analytics to ensure high-quality predictive data and lower investment risk and accelerate the timeline for bringing new therapies to market.

Transforming Imaging in Oncology Trials

“At Picture Health, we’re transforming how imaging is used in clinical trials.” said Trishan Arul, Co-founder and CEO of Picture Health “Collaborating with IAG enables us to integrate our multimodal AI biomarkers with their expertise in clinical trial imaging, creating a seamless experience for our clients both in clinical and real-world settings.”

About Image Analysis Group

Image Analysis Group (IAG) is a trusted partner to life sciences companies, combining deep expertise in medical imaging with the innovative power of its proprietary platform, DYNAMIKA™, to de-risk clinical development and accelerate the delivery of lifesaving therapies to patients. The IAG team designs and executes the imaging part of clinical trials that rely on radiological endpoints to demonstrate the safety and efficacy of new drug candidates. By using AI-powered endpoints and automating data management processes, with IAG you accelerate start-up and database lock, gain real-time visibility on trial progress, ensure clean data for regulatory submissions, and maximize patient recruitment speed. For nearly 20 years, the IAG team has helped reduce investment risk and accelerate study outcomes in over 700 trials, empowering biotech and pharmaceutical sponsors to make data-driven decisions with confidence.

Availability & Demo

Request a call to see a demo and discuss use of advanced imaging and bespoke imaging endpoints in your trial.

FAQ

Who are Picture Health?

Picture Health creates multimodal AI imaging biomarkers for precision oncology through its proprietary Px™ Platform, which integrates next-generation radiomics and pathomics. Its advanced and proprietary features classes–demonstrated in over 80 scientific publications–are biologically interpretable and capture key tumor properties and mechanisms including immune response and vascular complexity. Designed to work with routinely collected scans, the Px™ Platform enables custom prediction biomarker development without any additional tissue or testing. Picture Health partners with biopharma to improve patient characterization and enrichment, developing custom predictive biomarkers to unlock therapeutic insight and accelerate oncology drug development.

How can I use predictive analytics in Oncology Trial?

answer here.

How do I get started or request pricing?

Visit u003ca class=u0022u0022 href=u0022https://www-test.ia-grp.comu0022u003eNextLevel.aiu003c/au003e or schedule a call directly through the website to request a tailored demo or pricing.